MERCURYLAB Stock View

Mercury Laboratories Ltd
stock-view-header

icon 0.00 | 0.00
Market Cap ₹( Cr.)
957.60
Proj. P/E (x)
Proj. P/BV (x)
Proj. ROE (%)
Proj EV / EBITDA (x)
--
Proj. Revenue ( Cr.)

Stock View

Last Updated On.
01-Oct-2023
 

The average score for Mercury Laboratories Ltd stands at 6 against 8, three months back.

Mercury Laboratories Limited is an India-based pharmaceutical company. The Company operates through the Pharmaceuticals Products segment. The Company is engaged in the manufacturing and export of a range of pharmaceutical items. The products of the Company are in the segment of gynecology and pediatrics. Its products include antibiotic, antifungal, and antiviral formulations; anti-inflammatory formulations; antimalarial formulations; digestive formulations; hypoglycemic formulations; multivitamin formulations; central nervous system formulations; gynec formulations; CVS formulations; cough and cold formulations; and miscellaneous formulations, among others. Its antibiotic, antifungal, and antiviral formulations include azithromycin tablets, azithromycin dispersible tablets, griseofulvin tablets, metronidazole tablets, and others. Its anti-inflammatory formulations include dexamethasone tablets, glucosamine sulphate tablets, dexamethasone sodium phosphate injection, and others.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.


Technical Data

50 DMA(₹)
797.56
100 DMA(₹)
783.97
200 DMA(₹)
738.47
52 Weeks Range
510.30     1,000.00

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required